162 related articles for article (PubMed ID: 10501914)
1. Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243).
Sessa C; Zucchetti M; Ghielmini M; Bauer J; D'Incalci M; de Jong J; Naegele H; Rossi S; Pacciarini MA; Domenigoni L; Cavalli F
Cancer Chemother Pharmacol; 1999; 44(5):403-10. PubMed ID: 10501914
[TBL] [Abstract][Full Text] [Related]
2. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
5. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
Planting AS; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg ME; Luyten GP; de Leeuw K; de Boer-Dennert M; Wissel PS; Jewell RC; Paul EM; Purvis NB; Verweij J
Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444
[TBL] [Abstract][Full Text] [Related]
6. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
[TBL] [Abstract][Full Text] [Related]
7. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
10. A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.
Fokkema E; Verweij J; van Oosterom AT; Uges DR; Spinelli R; Valota O; de Vries EG; Groen HJ
Br J Cancer; 2000 Feb; 82(4):767-71. PubMed ID: 10732743
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762).
Vasey PA; Bissett D; Strolin-Benedetti M; Poggesi I; Breda M; Adams L; Wilson P; Pacciarini MA; Kaye SB; Cassidy J
Cancer Res; 1995 May; 55(10):2090-6. PubMed ID: 7743508
[TBL] [Abstract][Full Text] [Related]
13. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study.
Roh JK; Rha SY; Lee CI; Lee KH; Lee JJ; Shim HJ; Lee SD; Kim WB; Yang J; Kim SH; Lee MG
Int J Clin Pharmacol Ther; 1998 Jun; 36(6):312-9. PubMed ID: 9660038
[TBL] [Abstract][Full Text] [Related]
15. PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study.
Groen HJ; de Vries EG; Wynendaele W; van der Graaf WT; Fokkema E; Lechuga MJ; Poggesi I; Dirix LY; van Oosterom AT
Clin Cancer Res; 2001 Dec; 7(12):3928-33. PubMed ID: 11751484
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
Lockhart AC; Bukowski R; Rothenberg ML; Wang KK; Cooper W; Grover J; Appleman L; Mayer PR; Shapiro M; Zhu AX
Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
19. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.
Madden T; Tran HT; Beck D; Huie R; Newman RA; Pusztai L; Wright JJ; Abbruzzese JL
Clin Cancer Res; 2000 Apr; 6(4):1293-301. PubMed ID: 10778954
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
Cunningham C; Appleman LJ; Kirvan-Visovatti M; Ryan DP; Regan E; Vukelja S; Bonate PL; Ruvuna F; Fram RJ; Jekunen A; Weitman S; Hammond LA; Eder JP
Clin Cancer Res; 2005 Nov; 11(21):7825-33. PubMed ID: 16278405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
